menu toggle

Extensive packaging inventory, backed by data through our Climate Engineering and Optimisation labs.


With the advent of cell and gene therapies, getting those treatments to the right patients at the right time requires both manufacturers and suppliers to offer the most reliable and timely logistics possible. With the FDA projecting it will likely approve as many as 10 to 20 cell and gene therapies every year by 2025, the stakes are being raised to get new treatments to market. As many of those new therapies are based on an individual’s own cells, patients themselves have become a key part of the new supply chain.

Read the article to learn more about how cell and gene therapies will continue to develop over the coming years.